Among these, mutations in anaplastic lymphoma kinase (Alk) have been associated with lymphoma, neuroblastoma and non‐small‐cell lung cancers (Hallberg & Palmer, 2013), leading to the development of effective small molecule Alk inhibitors for clinical use (Kwak et al., 2010; Peters et al., 2017). This evidence concerns the gene ALK and neuroblastoma.